EAN News

The pandemic of COVID-19 continues to affect much of the world. Knowledge of diagnostic tests for SARS-CoV-2 is still evolving, and a clear understanding of the nature of the tests and interpretation of their findings is important.

I believe that the covid-19 pandemic showed us that we, as neurologists, are physicians first, and neurologists second. In other words, as neurology has increasingly developed into an acute care field, it is important that we are not only specialists in neurology, but also strive to build and keep expertise in fields adjacent to our core competences.

Rare neurological diseases are usually hereditary chronic disorders, affecting the central, peripheral nervous system and skeletal muscle, with clinically heterogeneous manifestations.

In this paper published in Neurology, the authors conducted a scoping review of available literature on COVID-19 to assess the potential impact on neurologists in terms of prevalent comorbidities and incidence of new neurological events in patients hospitalized with COVID-19.

n this paper recently published in JAMA, the authors evaluated the prevalence, intensity, and timing of an altered sense of smell or taste in mildly symptomatic patients with SARS-CoV-2 infection.

In this letter, recently published in the European Journal of Neurology, Sellner et al., emphasise that neurologists need to be part of the multidisciplinary team taking care of COVID-19 patients.

In this nice editorial, Prof. Johann Sellner discusses the possible role of translational neuroscience research in the current COVID-19 outbreak.

The current COVID-19 outbreak, caused by the novel SARS-CoV-2, has raised the possibility of potential neurotropic properties of this virus.

The aim of this randomised, double-blind, placebo-controlled, multicentre trial was to analyze the effects of Remdesivir in adult patients with severe COVID-19 infection.

The objective of this parallel, double-masked, randomized, phase IIb clinical trial, was to evaluate the safety and efficacy of 2 chloroquine diphosphate (CQ) dosages in patients with severe COVID-19. 81 adult patients who were hospitalized with SARS-CoV-2 infection were enrolled from March 23 to April 5, 2020, at a tertiary care facility in Manaus, Brazilian Amazon.

In this paper recently published in Movement Disorders, Prasad et al., surveyed the perceptions of 100 patients with Parkinson’s disease (PD) and their caregivers who were under follow-up at the National Institute of Mental Health and Neurosciences, Bengaluru, India on the implications of Covid-19 infection.

In this paper recently published in Movement Disorders, Antonini et al., report the outcome of 10 clinical cases of Parkinson’s Disease patients infected by SARS-CoV-2, collected from the experience at the Parkinson and Movement Disorders Unit in Padua, Italy and the Parkinson’s Foundation Centre of Excellence at King’s College Hospital in London, UK.

In this paper, Baracchini et al., share their single-center experience of the substantial changes in the acute stroke management pathway during the COVID-19 outbreak.

In this special report recently published in Stroke, Smith et al., assembled a multidisciplinary working group to develop consensus-based recommendations and an algorithm for evaluation and treatment of acute stroke patients eligible for endovascular therapy (EVT) during the COVID-19 pandemic, with the goal of minimizing the negative impact of COVID-19 on acute stroke patients and healthcare providers.

In this paper recently published in the Journal of Neurology, Neurosurgery, and Psychiatry, the authors describe the demographic, clinical, radiological and laboratory characteristics of six consecutive patients assessed between 1st and 16th April 2020 at the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK